[慢性肾脏疾病的心血管治疗]。

IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Herz Pub Date : 2023-10-01 Epub Date: 2023-09-11 DOI:10.1007/s00059-023-05205-2
Vincent Brandenburg, Turgay Saritas, Stephan H Schirmer, Kyrill Rogacev, Gunnar Henrik Heine
{"title":"[慢性肾脏疾病的心血管治疗]。","authors":"Vincent Brandenburg,&nbsp;Turgay Saritas,&nbsp;Stephan H Schirmer,&nbsp;Kyrill Rogacev,&nbsp;Gunnar Henrik Heine","doi":"10.1007/s00059-023-05205-2","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with combined cardiac and renal diseases are particularly challenging in the routine clinical practice due to the substantial risk profile for increased morbidity and mortality. As cardiorenal patients have often been underrepresented in randomized, controlled interventional trials, guideline recommendations regarding the choice of treatment are often weaker for these individuals than for cardiovascular patients without chronic kidney disease. Furthermore, there are limitations in the approval of certain medications depending on the kidney function. This review addresses some considerations in crucial treatment areas for patients with cardiovascular diseases, whose treatment is significantly influenced by concomitant chronic kidney disease.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"413-424"},"PeriodicalIF":1.1000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Cardiovascular treatment in chronic kidney disease].\",\"authors\":\"Vincent Brandenburg,&nbsp;Turgay Saritas,&nbsp;Stephan H Schirmer,&nbsp;Kyrill Rogacev,&nbsp;Gunnar Henrik Heine\",\"doi\":\"10.1007/s00059-023-05205-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients with combined cardiac and renal diseases are particularly challenging in the routine clinical practice due to the substantial risk profile for increased morbidity and mortality. As cardiorenal patients have often been underrepresented in randomized, controlled interventional trials, guideline recommendations regarding the choice of treatment are often weaker for these individuals than for cardiovascular patients without chronic kidney disease. Furthermore, there are limitations in the approval of certain medications depending on the kidney function. This review addresses some considerations in crucial treatment areas for patients with cardiovascular diseases, whose treatment is significantly influenced by concomitant chronic kidney disease.</p>\",\"PeriodicalId\":12863,\"journal\":{\"name\":\"Herz\",\"volume\":\" \",\"pages\":\"413-424\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Herz\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00059-023-05205-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Herz","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00059-023-05205-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

心脏和肾脏合并疾病的患者在常规临床实践中尤其具有挑战性,因为其发病率和死亡率增加的风险很大。由于心肾患者在随机对照介入试验中的代表性往往不足,因此与没有慢性肾脏疾病的心血管患者相比,这些患者的治疗选择指南建议往往较弱。此外,根据肾功能的不同,某些药物的批准也有限制。这篇综述阐述了心血管疾病患者在关键治疗领域的一些注意事项,其治疗受到伴随的慢性肾脏疾病的显著影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

[Cardiovascular treatment in chronic kidney disease].

[Cardiovascular treatment in chronic kidney disease].

Patients with combined cardiac and renal diseases are particularly challenging in the routine clinical practice due to the substantial risk profile for increased morbidity and mortality. As cardiorenal patients have often been underrepresented in randomized, controlled interventional trials, guideline recommendations regarding the choice of treatment are often weaker for these individuals than for cardiovascular patients without chronic kidney disease. Furthermore, there are limitations in the approval of certain medications depending on the kidney function. This review addresses some considerations in crucial treatment areas for patients with cardiovascular diseases, whose treatment is significantly influenced by concomitant chronic kidney disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Herz
Herz 医学-心血管系统
CiteScore
3.00
自引率
5.90%
发文量
61
审稿时长
4-8 weeks
期刊介绍: Herz is the high-level journal for further education for all physicians interested in cardiology. The individual issues of the journal each deal with specific topics and comprise review articles in English and German written by competent and esteemed authors. They provide up-to-date and comprehensive information concerning the speciality dealt with in the issue. Due to the fact that all relevant aspects of the pertinent topic of an issue are considered, an overview of the current status and progress in cardiology is presented. Reviews and original articles round off the spectrum of information provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信